A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal Cancer
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 09 Feb 2024 Planned End Date changed from 18 Jan 2024 to 18 Jul 2024.
- 09 Feb 2024 Planned primary completion date changed from 18 Jan 2024 to 18 Jul 2024.
- 09 Feb 2024 Status changed from recruiting to active, no longer recruiting.